Vivani Medical enters into agreement with Novo Nordisk to evaluate NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Nprepared by Vivaniovo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants. ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company's semaglutide drug implant. NPM-139, which utilizes Vivani's NanoPortal platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology associated with this agreement. Adam Mendelsohn, PhD, CEO of Vivani Medical. Adam Mendelsohn, PhD, CEO of Vivani Medical, holds the miniature semaglutide (GLP-1) implant designed for once- or twice-yearly administration. Adam Mendelsohn, Ph.D., Vivani President and CEO, stated: "The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary." Separately, Vivani expects to initiate a Phase 1, randomized, first-in-human study evaluating the NPM-139 semaglutide implant, with Wegovy(R) injections as an active comparator, in mid-2026. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM-139 to support the initiation of a Phase 2 dose-ranging study pending successful results of the Phase 1 study. About Vivani Medical, Inc. Leveraging its proprietary NanoPortal platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that are used in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from its expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission including the factors described in Vivani's most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer [email protected] (415) 506-8462 Investor and Media Relations Contact: Jami Taylor Investor and Media Relations Advisor [email protected] (415) 506-8462 GlobeNewswire Distribution ID 9758110

Vivani Medical enters into agreement with Novo Nordisk to evaluate NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. July 07, 2026 Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company's semaglutide drug implant. NPM-139, which utilizes Vivani's NanoPortal(TM) platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology associated with this agreement. Adam Mendelsohn, Ph.D., Vivani President and CEO, stated: "The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary." Separately, Vivani expects to initiate a Phase 1, randomized, first-in-human study evaluating the NPM-139 semaglutide implant, with Wegovy(R) injections as an active comparator, in mid-2026. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM-139 to support the initiation of a Phase 2 dose-ranging study pending successful results of the Phase 1 study. About Vivani Medical, Inc. Leveraging its proprietary NanoPortal(TM) platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that are used in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from its expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission including the factors described in Vivani's most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer [email protected] (415) 506-8462 Investor and Media Relations Contact: Jami Taylor Investor and Media Relations Advisor [email protected] (415) 506-8462 AAPR aggregates press releases and media statements from around the world to assist its news partners with identifying and creating timely and relevant news. All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.

Vivani spins out brain-computer interface business through Nasdaq reverse merger. The reverse merger will create Nasdaq-listed Cortigent Holdings, providing Vivani's brain-computer interface business with independent funding to accelerate vision restoration and neurorehabilitation technologies. Vivani Medical has agreed to spin out its brain-computer interface (BCI) business through a reverse merger with Nasdaq-listed communications technology company ClearOne, creating a new publicly traded neurotechnology company focused on restoring vision and motor function. Once the transaction closes, expected in the third quarter of 2026, ClearOne will be renamed Cortigent Holdings and will trade on the Nasdaq under the ticker CRGT. The move gives Vivani's neurotechnology division independent access to public capital while allowing the parent company to concentrate on its long-acting drug implant portfolio. Creating a standalone brain-computer interface company. Under the agreement, Vivani will receive 12.5 million shares of ClearOne common stock and will own between 59.4% and 67.5% of the combined company, depending on the final financing structure. Existing ClearOne shareholders will retain between 12.7% and 14.4% ownership. Although ClearOne currently develops professional audio and video collaboration systems, that business will become a legacy, non-core operation following completion of the merger as the company shifts its strategic focus towards neurotechnology. Investor enthusiasm was immediate. Following the announcement, ClearOne's share price more than doubled during trading, highlighting growing interest in the brain-computer interface sector. Building a pipeline focused on restoring vision and movement. The new Cortigent Holdings will inherit a portfolio of implantable neurostimulation technologies targeting significant unmet neurological needs. Its lead programmes include: * Orion, a brain-computer interface implant designed to restore functional vision in blind patients. * Argus II, a retinal prosthesis intended to provide artificial vision for people living with severe retinitis pigmentosa. The company is also developing a next-generation neurostimulation device designed to help restore arm and hand movement following stroke-related paralysis, expanding its focus beyond vision restoration into neurorehabilitation. These technologies originated from Second Sight Medical before becoming part of Vivani following its merger with Nano Precision Medical in 2022. Funding future development. Alongside the merger, ClearOne plans to raise between $10 million and $15 million through a share offering to support continued clinical and product development. For Vivani, the transaction also delivers strategic benefits beyond financing. By separating Cortigent into an independent public company, Vivani expects to reduce ongoing investment requirements while sharpening its focus on developing long-acting implantable drug delivery technologies. The structure allows both businesses to pursue distinct growth strategies while maintaining Vivani as the majority shareholder in the new neurotechnology company. Why the deal matters. The transaction reflects several broader trends emerging across healthcare innovation: * Brain-computer interface technologies are attracting increasing commercial and investor interest. * Companies are using reverse mergers to access public markets more quickly than through traditional IPOs. * Neurotechnology developers are expanding beyond research into commercially focused clinical pipelines. * Investors are showing growing confidence in implantable devices targeting neurological disorders and rehabilitation. The market opportunity is substantial. Industry forecasts project the global neurology devices market to exceed $25 billion by 2034, while some analysts estimate the long-term addressable market for healthcare-focused brain-computer interfaces could eventually reach hundreds of billions of dollars as the technology matures. Summary. Vivani Medical has agreed to merge its Cortigent neurotechnology business with ClearOne, creating a new publicly listed company dedicated to brain-computer interface technologies. The transaction provides Cortigent with independent access to public markets while enabling Vivani to focus on its core drug delivery platform. As investment and clinical development accelerate across neurotechnology, the deal highlights the growing commercial momentum behind brain-computer interfaces aimed at restoring vision, movement and neurological function. Discover how nuaxia can support your next medical education initiative: